Cargando…

Antiphospholipid Antibody Titers and Clinical Outcomes in Patients with Recurrent Miscarriage and Antiphospholipid Antibody Syndrome: A Prospective Study

BACKGROUND: The management of patients with recurrent miscarriage (RM) and antiphospholipid antibody syndrome (APS) includes prolonged treatment with heparin and aspirin, starting from the confirmation of pregnancy and continuing until 6 weeks after birth. This study was conducted to determine the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yu, Wang, Hai-Yan, Qiao, Jie, Liu, Ping, Chi, Hong-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308007/
https://www.ncbi.nlm.nih.gov/pubmed/28139508
http://dx.doi.org/10.4103/0366-6999.198934
_version_ 1782507472955637760
author Song, Yu
Wang, Hai-Yan
Qiao, Jie
Liu, Ping
Chi, Hong-Bin
author_facet Song, Yu
Wang, Hai-Yan
Qiao, Jie
Liu, Ping
Chi, Hong-Bin
author_sort Song, Yu
collection PubMed
description BACKGROUND: The management of patients with recurrent miscarriage (RM) and antiphospholipid antibody syndrome (APS) includes prolonged treatment with heparin and aspirin, starting from the confirmation of pregnancy and continuing until 6 weeks after birth. This study was conducted to determine the relationship between changes in antiphospholipid antibody titers and clinical outcomes. The effect of a shortened treatment regimen was also evaluated. METHODS: A prospective study of 123 patients with RM and APS between March 2012 and May 2014 was conducted. Patients were pretreated with a low dose of prednisone plus aspirin before pregnancy, and heparin was added after conception. The levels of antiphospholipid antibodies and pregnancy outcomes were evaluated. RESULTS: All patients were positive for anti-β2-glycoprotein 1 (anti-β2-GP1) IgM. After prepregnancy treatment with low-dose prednisone plus aspirin, 99 of 123 patients became pregnant, and 87 of those pregnancies resulted in successful live births, while 12 resulted in miscarriage, showing a success rate of 87.9%. In the live birth group, levels of anti-β2-GP1 were 56.8 ± 49.0 RU/ml before the pretreatment regimen, 32.1 ± 26.0 RU/ml after 2 months of pretreatment, and 24.1 ± 23.1 RU/ml during early pregnancy (P < 0.05). In the miscarriage group, antiphospholipid antibody titers were 52.8 ± 30.7 RU/ml before pretreatment, 38.5 ± 34.2 RU/ml after pretreatment, and 33.9 ± 24.7 RU/ml during early pregnancy; the decrease in antiphospholipid antibodies was lower in the miscarriage group than in the live birth group (P < 0.05). Of the 24 infertile patients, the average antibody titer did not decline after pretreatment (P = 0.802). CONCLUSIONS: Anti-β2-GP1 IgM was the predominant form of antibody in patients with RM and APS. The decreases in antiphospholipid antibody titers correlated with better pregnancy outcomes. The shorter treatment regimen was effective and economical.
format Online
Article
Text
id pubmed-5308007
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-53080072017-02-17 Antiphospholipid Antibody Titers and Clinical Outcomes in Patients with Recurrent Miscarriage and Antiphospholipid Antibody Syndrome: A Prospective Study Song, Yu Wang, Hai-Yan Qiao, Jie Liu, Ping Chi, Hong-Bin Chin Med J (Engl) Original Article BACKGROUND: The management of patients with recurrent miscarriage (RM) and antiphospholipid antibody syndrome (APS) includes prolonged treatment with heparin and aspirin, starting from the confirmation of pregnancy and continuing until 6 weeks after birth. This study was conducted to determine the relationship between changes in antiphospholipid antibody titers and clinical outcomes. The effect of a shortened treatment regimen was also evaluated. METHODS: A prospective study of 123 patients with RM and APS between March 2012 and May 2014 was conducted. Patients were pretreated with a low dose of prednisone plus aspirin before pregnancy, and heparin was added after conception. The levels of antiphospholipid antibodies and pregnancy outcomes were evaluated. RESULTS: All patients were positive for anti-β2-glycoprotein 1 (anti-β2-GP1) IgM. After prepregnancy treatment with low-dose prednisone plus aspirin, 99 of 123 patients became pregnant, and 87 of those pregnancies resulted in successful live births, while 12 resulted in miscarriage, showing a success rate of 87.9%. In the live birth group, levels of anti-β2-GP1 were 56.8 ± 49.0 RU/ml before the pretreatment regimen, 32.1 ± 26.0 RU/ml after 2 months of pretreatment, and 24.1 ± 23.1 RU/ml during early pregnancy (P < 0.05). In the miscarriage group, antiphospholipid antibody titers were 52.8 ± 30.7 RU/ml before pretreatment, 38.5 ± 34.2 RU/ml after pretreatment, and 33.9 ± 24.7 RU/ml during early pregnancy; the decrease in antiphospholipid antibodies was lower in the miscarriage group than in the live birth group (P < 0.05). Of the 24 infertile patients, the average antibody titer did not decline after pretreatment (P = 0.802). CONCLUSIONS: Anti-β2-GP1 IgM was the predominant form of antibody in patients with RM and APS. The decreases in antiphospholipid antibody titers correlated with better pregnancy outcomes. The shorter treatment regimen was effective and economical. Medknow Publications & Media Pvt Ltd 2017-02-05 /pmc/articles/PMC5308007/ /pubmed/28139508 http://dx.doi.org/10.4103/0366-6999.198934 Text en Copyright: © 2017 Chinese Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Song, Yu
Wang, Hai-Yan
Qiao, Jie
Liu, Ping
Chi, Hong-Bin
Antiphospholipid Antibody Titers and Clinical Outcomes in Patients with Recurrent Miscarriage and Antiphospholipid Antibody Syndrome: A Prospective Study
title Antiphospholipid Antibody Titers and Clinical Outcomes in Patients with Recurrent Miscarriage and Antiphospholipid Antibody Syndrome: A Prospective Study
title_full Antiphospholipid Antibody Titers and Clinical Outcomes in Patients with Recurrent Miscarriage and Antiphospholipid Antibody Syndrome: A Prospective Study
title_fullStr Antiphospholipid Antibody Titers and Clinical Outcomes in Patients with Recurrent Miscarriage and Antiphospholipid Antibody Syndrome: A Prospective Study
title_full_unstemmed Antiphospholipid Antibody Titers and Clinical Outcomes in Patients with Recurrent Miscarriage and Antiphospholipid Antibody Syndrome: A Prospective Study
title_short Antiphospholipid Antibody Titers and Clinical Outcomes in Patients with Recurrent Miscarriage and Antiphospholipid Antibody Syndrome: A Prospective Study
title_sort antiphospholipid antibody titers and clinical outcomes in patients with recurrent miscarriage and antiphospholipid antibody syndrome: a prospective study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308007/
https://www.ncbi.nlm.nih.gov/pubmed/28139508
http://dx.doi.org/10.4103/0366-6999.198934
work_keys_str_mv AT songyu antiphospholipidantibodytitersandclinicaloutcomesinpatientswithrecurrentmiscarriageandantiphospholipidantibodysyndromeaprospectivestudy
AT wanghaiyan antiphospholipidantibodytitersandclinicaloutcomesinpatientswithrecurrentmiscarriageandantiphospholipidantibodysyndromeaprospectivestudy
AT qiaojie antiphospholipidantibodytitersandclinicaloutcomesinpatientswithrecurrentmiscarriageandantiphospholipidantibodysyndromeaprospectivestudy
AT liuping antiphospholipidantibodytitersandclinicaloutcomesinpatientswithrecurrentmiscarriageandantiphospholipidantibodysyndromeaprospectivestudy
AT chihongbin antiphospholipidantibodytitersandclinicaloutcomesinpatientswithrecurrentmiscarriageandantiphospholipidantibodysyndromeaprospectivestudy